|Date||21 April 2022 (Thursday)|
|Time||7:30 – 8:45pm|
|Topic||Management of diabetic kidney disease in 2022: what’s hot?|
|Format||Live Webinar (Zoom)|
|Speaker||Professor Sydney Chi Wai TANG
|Moderator||Professor Richard YH YU S.B.S.
|Agenda||7:00 – 7:25pm | Online Reception
7:25 – 7:30pm | Welcome Message
7:30 – 8:45pm | Lecture and Q&A Session
Content of Webinar
- Diabetic kidney disease (DKD) has reached epidemic proportions in many parts of the world. It is the top cause of treated kidney replacement therapy in many Asian countries. In China, a large-scale hospital-based survey found that DKD exceeded glomerulonephritis as the most prevalent cause of kidney failure since 2011 and the China Kidney Disease Network (CKD-NET) 2016 Annual Data Report, published in 2020, revealed DKD to also be the top cause of CKD, accounting for 26.7% of patients with CKD.
- Until 2016, there has been no specific therapy for DKD apart from renin-angiotensin-aldosterone blockers. SGLT2 inhibitors have certainly been under the spotlight in diabetic and even nondiabetic CKD since then. Key RCTs include EMPA-REG, CREDENCE and DAPA-CKD. Thereafter, we have the addition of the glucagon-like peptide 1 receptor agonist (LEADER), endothelin type A receptor antagonist (SONAR) and non-steroidal mineralocorticoid receptor antagonist (FIDELIO) to the treatment armamentarium. International guidelines from the Asian Pacific Society of Nephrology and KDIGO have both developed a set of clinical guidelines published in Oct 2020 on the management of DKD. They focus on the recognition, screening, monitoring and management of diabetic kidney disease.
- Clinical care of patients with diabetes and CKD should integrate new treatment options with existing management strategies based on high quality evidence. Here, comprehensive care of patients with diabetes and CKD, glycaemic monitoring and targets, antihyperglycaemic therapies using novel approaches including and beyond SGLT2i in patients with diabetes and CKD will be discussed.